Home Cart Sign in  
Chemical Structure| 256376-24-6 Chemical Structure| 256376-24-6

Structure of BAY 41-2272
CAS No.: 256376-24-6

Chemical Structure| 256376-24-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY 41-2272 is an activator of guanylate cyclases (sGC).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BAY 41-2272

CAS No. :256376-24-6
Formula : C20H17FN6
M.W : 360.39
SMILES Code : NC1=NC(C2=NN(CC3=CC=CC=C3F)C4=NC=CC=C42)=NC=C1C5CC5
MDL No. :MFCD06411391
InChI Key :ATOAHNRJAXSBOR-UHFFFAOYSA-N
Pubchem ID :9798973

Safety of BAY 41-2272

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of BAY 41-2272

GPCR

Isoform Comparison

Biological Activity

Description
BAY 41-2272, an oral and soluble activator of guanylate cyclases (sGC), enhances sGC activity 400-fold in combination with NO. It effectively reduces cardiac workload and boosts cardiac output, making it suitable for cardiovascular disease research[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
msGC-NT (truncated Manduca sexta sGC) 5 µM To investigate the effect of BAY 41-2272 on the heme pocket of sGC. The results showed that upon binding of BAY 41-2272, a new fast phase appeared during CO photolysis, indicating that CO molecules were trapped and recaptured in the heme pocket J Am Chem Soc. 2008 Nov 26;130(47):15748-9
UM47 cells 10 μM 72 h significantly reduced clonogenic survival Cancer Lett. 2016 Jan 28;370(2):279-85
CAL27 cells 10 μM 72 h significantly increased apoptosis Cancer Lett. 2016 Jan 28;370(2):279-85
CAL27 cells 10 μM 24 h significantly decreased cell proliferation Cancer Lett. 2016 Jan 28;370(2):279-85
CAL27 cells 10 μM 72 h decreased cell viability, induced apoptosis Cancer Lett. 2016 Jan 28;370(2):279-85
human lung slices (PCLS) 10, 20, or 50 μM 30 min To test the bronchodilatory effect of BAY 41-2272 in human lung slices, results showed that BAY 41-2272 could dilate preconstricted small airways. Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2355-62
Platelets 10 μM 10 min To evaluate the effect of BAY 41-2272 on thrombin-induced P-selectin expression in platelets. Results showed that BAY 41-2272 significantly reversed thrombin-induced P-selectin expression. Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1386-91
Human umbilical vein endothelial cells (HUVECs) 10 μM 30 min to 5 h To evaluate the effect of BAY 41-2272 on IL-1β-induced P-selectin expression. Results showed that BAY 41-2272 significantly attenuated IL-1β-induced P-selectin expression but had no effect on E-selectin and ICAM-1 expression. Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1386-91
Human embryonic stem cells (H-9) 1-9 μM 24 h To investigate the effect of BAY 41-2272 on the differentiation of human embryonic stem cells into myocardial cells, showing a dose-dependent increase in Nkx2.5 mRNA expression. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18924-9
Mouse embryonic stem cells (EZ1) 1-3 μM 8 days To investigate the effect of BAY 41-2272 on the differentiation of mouse embryonic stem cells into myocardial cells, showing a 65% to 2-fold increase in Nkx2.5 mRNA expression. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18924-9
CAL27 cells 10 μM 60 min increased intracellular cGMP content, significantly higher than control Cancer Lett. 2016 Jan 28;370(2):279-85
Washed platelets 10 μM 3 min To evaluate the inhibitory effect of BAY 41-2272 on platelet aggregation and its impact on cGMP levels. Results showed that BAY 41-2272 significantly inhibited platelet aggregation and increased cGMP levels. Cardiovasc Diabetol. 2012 Jan 16;11:5

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Lambs Acute pulmonary hypertension model Inhalation 0.05, 0.1, and 0.15 mg/kg 2-hour intervals between each dose Inhalation of BAY 41-2272 produced dose-dependent pulmonary vasodilation and increased transpulmonary cGMP release without significant effect on mean arterial pressure. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1138-45
Mice Ovalbumin (OVA) and house dust mite extract (HDME)-induced allergic asthma models Intratracheal administration 30 μg/kg Single dose, 30 minutes before testing To test the bronchodilatory effect of BAY 41-2272 in allergic asthma mouse models, results showed that BAY 41-2272 could significantly reduce or eliminate airway hyperresponsiveness. Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2355-62
Mice ENOS knockout and wild-type mice Tissue superfusion 0.3-1 μM Single administration, observation time not specified To evaluate the effect of BAY 41-2272 on leukocyte rolling and adhesion. Results showed that BAY 41-2272 significantly reduced leukocyte rolling and adhesion in eNOS knockout mice to levels observed in WT animals. Additionally, BAY 41-2272 inhibited IL-1β-induced leukocyte rolling and adhesion. Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1386-91

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.87mL

2.77mL

1.39mL

27.75mL

5.55mL

2.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories